10-Q: VSee Health Q2 Loss Widens 1050%, Going Concern Doubts Mount

VSee Health, Inc. reported a significant 1050% increase in net loss for Q2 2025, raising substantial doubt about its ability to continue as a going concern amidst internal control weaknesses and ongoing financing needs.

Summary

• Net loss for the six months ended June 30, 2025, increased by 1050% to $(6,572,723) from $(571,352) in the prior year.
• Revenue for the six months ended June 30, 2025, grew by 101% to $6,711,604, primarily due to the iDoc acquisition and the HHS contract.
• Gross margin increased by 71% to $3,448,463 for the six months ended June 30, 2025.
• Operating expenses surged by 165% to $7,534,521 for the six months ended June 30, 2025, driven by the iDoc acquisition, DHAC recapitalization, and increased compensation.
• The company reported a total stockholders deficit of $(5,736,304) as of June 30, 2025, compared to $(18,488) as of December 31, 2024.
• Management identified material weaknesses in internal control over financial reporting, including insufficient accounting personnel and ineffective IT General Controls (ITGC).
• The company's ability to continue as a going concern is in substantial doubt due to persistent operating losses and deteriorating liquidity.

Sentiment

Score: 2

Explanation: The company's financial position is highly distressed, evidenced by a 1050% increase in net loss, a significantly worsening stockholders deficit, and an explicit 'going concern' warning from management. Material weaknesses in internal controls, a history of financial restatements, and multiple debt defaults underscore severe operational and financial mismanagement. While revenue growth is noted, it is overshadowed by escalating operating expenses and a precarious liquidity situation. The heavy reliance on continuous financing and related party transactions indicates a precarious financial position.

Positives

• Total revenues increased by 101% to $6,711,604 for the six months ended June 30, 2025, driven by the iDoc acquisition and new contracts.
• Gross margin increased by 71% to $3,448,463 for the six months ended June 30, 2025.
• Net cash used in operating activities decreased significantly to $(765,094) for the six months ended June 30, 2025, from $(2,594,214) in the prior year, indicating improved operational cash burn.
• Secured new contracts with larger hospitals and entered new markets, with service commencing for a new client in Q3.
• Received $167,468 in other income, primarily from the United States Employee Retention Credit (ERC) for the iDoc business.

Negatives

• Net loss increased by 1050% to $(6,572,723) for the six months ended June 30, 2025, compared to $(571,352) in the prior year.
• Operating expenses increased by 165% to $7,534,521 for the six months ended June 30, 2025.
• Total stockholders deficit significantly worsened to $(5,736,304) as of June 30, 2025, from $(18,488) as of December 31, 2024.
• Cash balance decreased to $291,595 as of June 30, 2025, from $326,115 as of December 31, 2024.
• Net cash provided by financing activities decreased to $746,040 for the six months ended June 30, 2025, from $3,597,841 in the prior year, indicating reduced access to capital compared to the previous period.
• Multiple notes payable and lines of credit are currently in default.
• Prior period financial statements were restated due to material misstatements related to sales and use taxes, revenue recognition, and accrued expenses.
• The company has substantial doubt about its ability to continue as a going concern.

Risks

• Substantial doubt about the company's ability to continue as a going concern due to persistent operating losses and deteriorating liquidity.
• Material weaknesses in internal control over financial reporting, including insufficient accounting personnel, ineffective ITGC, and lack of formalized control environment, which contributed to the inability to timely file the report.
• Ongoing litigation related to alleged breach of contract and unjust enrichment, seeking significant payments.
• Default on multiple promissory notes and lines of credit, which could lead to acceleration of payments.
• High customer concentration, with two customers representing 35% of accounts receivable and one customer accounting for 29% of total revenue for the three months ended June 30, 2025.
• High vendor concentration, with one vendor representing 20% of total accounts payable and accrued liabilities as of June 30, 2025.
• Potential sales tax exposure, with a recorded liability of $1,157,346 as of June 30, 2025.
• Reliance on future financing to support working capital needs and growth initiatives, with no assurance of successful or timely alleviation of going concern doubts.
• Significant dilution risk for shareholders from convertible notes and the Equity Line of Credit (ELOC) agreement.

Future Outlook

Management believes future performance depends on the rapid transformation of the telehealth market, the ability to expand within the market and attract new customers, and continuous innovation in new product offerings. The company plans to leverage its industry relationships with government, hospital systems, and insurance providers to increase its customer base and invest in new technology to develop features, modules, and solutions, aiming to address current limitations in telehealth penetration and become a long-term partner in the rapidly changing healthcare industry.

Management Comments

• Management has determined that the liquidity condition and historical operating losses raises substantial doubt about its ability to continue as a going concern for a period of time of least one year after the date that the accompanying condensed consolidated financial statements are issued.
• There is no assurance that the Company’s plans to alleviate such concerns will be successful or successful within one year after the date the condensed consolidated financial statements are issued.
• We lack the resources to employ additional personnel to help mitigate these material weaknesses and we foresee that these material weaknesses will not be remediated until we receive additional funding to support our accounting department.
• We cannot assure you that these or other measures will fully remediate the material weakness in a timely manner.
• Notwithstanding the identified material weakness, our management believes that the consolidated financial statements included in this report fairly represent in all material respects our financial condition, results of operations and cash flows at and for the periods presented in accordance with U.S. GAAP.

Industry Context

The telehealth market is undergoing rapid transformation, with significant growth potential, particularly within hospital systems. However, telehealth solutions have not fully penetrated medicine and hospital systems, representing less than 1% of total healthcare spending. This is attributed to existing video/hardware/software not being healthcare-specific, poor integration of remote monitoring devices, suboptimal backend software coordination, and functional limitations of early telemedicine companies. VSee Health aims to address these gaps with its scalable, API-driven platform and high-acuity patient care services, positioning itself as a solution provider in a market seeking improved integration, real-time diagnostics, and customizable workflows, especially in a post-COVID environment marked by physician burnout and patient access challenges.

Management Changes

Corporate Governance

Legal Proceedings

• A lawsuit filed on July 25, 2024, alleging breach of contract and unjust enrichment, seeking payment under promissory notes, payments related to the Encompass Acquisition Agreement, prejudgment and post-judgment interest, and attorneys' fees. The company denied allegations and filed a counterclaim. Settlement discussions are ongoing in federal court.

Related Party Transactions

• Due from related party (iDoc's former CEO, Imoigele Aisiku) decreased to $241,122 as of June 30, 2025, from $531,656 as of December 31, 2024. These are unsecured and non-interest-bearing.
• Promissory notes with Milton Chen (then CEO of VSee Lab) totaling $323,000 principal, all in default, with accrued interest of $64,991, $72,459, and $27,253 respectively as of June 30, 2025.
• Promissory note with a board member (iDoc) for $200,000 principal, bearing no interest, with security rights to telepresence robots, with $141,651 outstanding as of June 30, 2025.
• Quantum Convertible Note ($3,000,000 principal) with Quantum Investor, where SCS Capital Partners LLC (a Sponsor affiliate) owns approximately 40.74% of the investor.
• Consulting Services Agreement with SCS, LLC (Sponsor affiliate) for $12,500 per month for consulting and $2,500 per month for access to remote office space, plus stock issuances.
• Advances due to Sponsor and certain Sponsor affiliates of $51,900 as of June 30, 2025, which are non-interest-bearing and due on demand.
• Co-CEOs Imo Aisiku and Milton Chen, and CFO Jerry Leonard, personally guaranteed the Initial MBLA Note and Mr. Aisiku pledged his shares as security for the MBLA.

Stakeholder Impact

• Shareholders face significant dilution risk from numerous convertible notes and the Equity Line of Credit. The substantial increase in net loss and going concern warning indicate high investment risk. The worsening stockholders deficit is a negative signal.
• Employees with stock options granted under the 2024 Plan have potential upside, but the common stock issuance obligation for iDoc employees is classified as a liability, indicating uncertainty regarding its settlement.
• Customers may benefit from expanded service offerings due to the iDoc acquisition and new contracts (e.g., HHS), but the company's financial instability could pose long-term risks to service continuity and reliability.
• Suppliers and vendors, particularly the major vendor representing 20% of accounts payable, face concentration risk. Delays in payments or financial distress could impact relationships and future supply.
• Creditors are exposed to high credit risk due to multiple notes being in default and the existence of forbearance agreements. The personal guarantees by management on new loans indicate increased risk for key executives.

Next Steps

• Continue negotiations with an investor for additional financing to support working capital needs and growth initiatives.
• Remediate material weaknesses in internal control over financial reporting, contingent on additional funding for the accounting department.
• Continue settlement discussions for the pending lawsuit related to alleged breach of contract and unjust enrichment.
• Repay the revised forbearance agreement in full by November 2025.
• Make weekly payments of $7,500 for 12 weeks, followed by 40 weekly payments of $15,862.50 under the Initial MBLA Note.
• Comply with covenants under the MBLA, prohibiting additional indebtedness (other than ordinary course trade debt) and dividend payments.
• Comply with terms of the October 2025 Note, including prohibitions on variable rate transactions and requirements for more favorable terms to the Note Investor.

Key Dates

Recommendation

The company's financial position is highly distressed, evidenced by a 1050% increase in net loss, a significantly worsening stockholders deficit, and an explicit 'going concern' warning from management. Material weaknesses in internal controls, a history of financial restatements, and multiple debt defaults underscore severe operational and financial mismanagement. While revenue growth is noted, it is overshadowed by escalating operating expenses and a precarious liquidity situation. The heavy reliance on dilutive financing and related party transactions, coupled with personal guarantees from management on new loans, signals extreme risk. Investors face substantial downside potential, including significant dilution and potential bankruptcy, making the stock a strong sell.

Keywords

Telehealth, Healthcare Technology, SEC Filing, 10-Q, Financial Results, Net Loss, Revenue Growth, Going Concern, Internal Controls, Convertible Debt, Equity Line of Credit, Related Party Transactions, Litigation, VSee Health, iDoc, Financial Reporting